Literature DB >> 8159178

What is the best diagnostic index of conduction block and temporal dispersion?

S J Oh1, D E Kim, H R Kuruoglu.   

Abstract

In order to find the best diagnostic index of conduction block and abnormal temporal dispersion, the amplitude, duration, and area of the compound muscle action potentials (CMAP) were studied in 40 normal controls and 28 patients with acquired demyelinating neuropathies. In the normal subjects, there was a substantial difference among the various nerves in the degree of CMAP amplitude reduction and CMAP duration prolongation with proximal stimulation, and thus different criteria should be used for conduction block or abnormal temporal dispersion for a given nerve. In 28 patients with demyelinating neuropathy, 58 of 207 (28%) tested nerve segments showed nerve conduction velocity (NCV) evidence of demyelination. To identify "demyelination" in these segments, conduction block was best detected by the total area method in 71% of cases, and abnormal temporal dispersion was best by the negative-peak duration method. This study showed that the best diagnostic index for conduction block is the total area method and for abnormal temporal dispersion, the negative-peak duration method.

Entities:  

Mesh:

Year:  1994        PMID: 8159178     DOI: 10.1002/mus.880170504

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  13 in total

Review 1.  Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy.

Authors:  David S Saperstein; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2003-01       Impact factor: 5.081

2.  The effect of treatment upon temporal dispersion in IvIg responsive multifocal motor neuropathy.

Authors:  A Ghosh; A Virgincar; R Kennett; M Busby; M Donaghy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

3.  A practical definition of conduction block in IvIg responsive multifocal motor neuropathy.

Authors:  A Ghosh; M Busby; R Kennett; K Mills; M Donaghy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

Review 4.  Diagnosis of acute neuropathies.

Authors:  Clarissa Crone; Christian Krarup
Journal:  J Neurol       Date:  2007-09-21       Impact factor: 4.849

5.  Acute Motor Conduction Block Neuropathy: Another Distinct Variant of Guillain-Barre Syndrome.

Authors:  Nilüfer Erdoğmuş Ince; M Fevzi Öztekin; Neşe Öztekin
Journal:  Noro Psikiyatr Ars       Date:  2014-03-01       Impact factor: 1.339

6.  Axon loss is an important determinant of weakness in multifocal motor neuropathy.

Authors:  J T H Van Asseldonk; L H Van den Berg; S Kalmijn; R M Van den Berg-Vos; C H Polman; J H J Wokke; H Franssen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06       Impact factor: 10.154

Review 7.  Immunoglobulin for multifocal motor neuropathy.

Authors:  Stephen Keddie; Filip Eftimov; Leonard H van den Berg; Ruth Brassington; Rob J de Haan; Ivo N van Schaik
Journal:  Cochrane Database Syst Rev       Date:  2022-01-11

8.  The diagnostic sensitivity of different F wave parameters.

Authors:  F Weber
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-10       Impact factor: 10.154

9.  Prevalence of anti-ganglioside antibodies and their clinical correlates with guillain-barré syndrome in Korea: a nationwide multicenter study.

Authors:  Jong Kuk Kim; Jong Seok Bae; Dae-Seong Kim; Susumu Kusunoki; Jong Eun Kim; Ji Soo Kim; Young-Eun Park; Ki-Jong Park; Hyun Seok Song; Sun Young Kim; Jeong-Geun Lim; Nam-Hee Kim; Bum Chun Suh; Tai-Seung Nam; Min Su Park; Young-Chul Choi; Eun Hee Sohn; Sang-Jun Na; So Young Huh; Ohyun Kwon; Su-Yun Lee; Sung-Hoon Lee; Sun-Young Oh; Seong-Hae Jeong; Tae-Kyeong Lee; Dong Uk Kim
Journal:  J Clin Neurol       Date:  2014-04-23       Impact factor: 3.077

10.  Chronic dysimmune neuropathies: Beyond chronic demyelinating polyradiculoneuropathy.

Authors:  Satish V Khadilkar; Shrikant S Deshmukh; Pramod D Dhonde
Journal:  Ann Indian Acad Neurol       Date:  2011-04       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.